Neurocrine Biosciences presents a new analysis that benchmarks clinically meaningful change in general health reported by patients with tardive dyskinesia. Company announcement - FT.com.
Neurocrine Biosciences presents a new analysis that benchmarks clinically meaningful change in general health reported by patients with tardive dyskinesia. Company announcement - FT.com.